Bullish Moving Averages
10
Bearish Moving Averages
6
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
135.00Today’s High
139.4052W low
112.4052W High
202.50Open Price
135.00Prev. Close
127.7500Volume
89932.00Value
12300898.96Fundamentals
Market Cap
837.80
Price to Earnings
-891.20
Price to Book Value
1.00
Dividend Yield
0.00
PE to Growth
-9.20
Op Revenue TTM
559.17
Net Profit TTM
-0.94
Cash From Operating Activity
-0.10
Return on Equity %
-0.13
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
25 Jul, 2024
52.8
Week
46.4
Month
45.5
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
137.06
PIVOT
First Resistance
139.13
Second Resistance
141.47
Third Resistance
143.54
First Support
134.72
Second Support
132.65
Third Support
130.31
Relative Strength Index
50.97
Money Flow Index
37.95
MACD
0.18
MACD Signal
0.6
Average True Range
5.35
Average Directional Index
20.91
Rate of Change (21)
-0.57
Rate of Change (125)
-17.38
Commodity Channel Index
-9.2
Williams %R
-61.5
BETA
1 Month
0.97
3 Month
1
1 Year
0.87
3 Year
0.51
PRICE CHANGE ANALYSIS
↓ -0.4%
1 Week
Low
High
130
139.41
↑ 2.61%
1 Month
Low
High
130
147.6
↓ -3.64%
3 Months
Low
High
112.35
149.9
↓ -17.05%
6 Months
Low
High
112.35
169.7
↑ 11.38%
1 Year
Low
High
112.35
202.5
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 96.76 | 98.28 | 96.72 | 92.75 | 85.29 | 81.68 | 56.66 | 67.87 | 44.07 | 40.86 | 122.73 | 40.41 | 87.61 | |
| Operating Expenses Qtr | 89.61 | 88.59 | 84.63 | 82.60 | 71.59 | 59.68 | 55.06 | 133.36 | 60.88 | 54.92 | 136.71 | 55.67 | 95.97 | |
| Operating Profit Qtr | -9.24 | 6.64 | 9.96 | 6.81 | 3.43 | 12.29 | -6.32 | -72.02 | -19.38 | -16.44 | -17.45 | -19.41 | -16.11 | |
| EBIDT Qtr Cr | 7.15 | 9.69 | 12.09 | 10.15 | 13.70 | 22.00 | 1.60 | -65.49 | -16.81 | -14.06 | -13.98 | -15.26 | -8.36 | |
| Depreciation Qtr | 5.14 | 5.21 | 5.34 | 5.40 | 5.90 | 6.08 | 6.24 | 6.28 | 7.06 | 6.46 | 6.48 | 6.43 | 6.57 | |
| Net Profit Qtr | -1.37 | 0.43 | 3.20 | 1.29 | -19.69 | 13.24 | -6.85 | -74.24 | -25.31 | -22.43 | -22.37 | -23.47 | -18.31 | |
| Basic EPS Qtr | -0.22 | 0.07 | 0.52 | 0.21 | -3.21 | 2.16 | -1.12 | -12.12 | -4.13 | -3.66 | -3.65 | -3.83 | -2.99 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 384.51 | 291.50 | 248.07 | 364.30 | 188.96 | |
| Operating Expenses Annual Cr | 345.43 | 319.69 | 308.17 | 343.07 | 220.32 | |
| Operating Profit Annual | 14.17 | -62.63 | -72.67 | 0.49 | -62.23 | |
| Operating Profit Margin Annual % | 3.69 | -21.48 | -29.29 | 0.13 | -32.93 | |
| Total Expenses Annual Cr | 380.30 | 354.25 | 341.65 | 377.15 | 252.49 | |
| EBIDT Annual Cr | 39.08 | -28.19 | -60.10 | 21.24 | -31.36 | |
| EBIDT Annual margin % | 10.16 | -9.67 | -24.23 | 5.83 | -16.59 | |
| Depreciation | 21.09 | 24.50 | 26.43 | 26.57 | 26.91 | |
| PAT Before ExtraOrdinary Items Annual Cr | 3.55 | -87.54 | -93.58 | -14.41 | -96.02 | |
| Net Profit Annual | 3.55 | -87.54 | -93.58 | -14.44 | -153.07 | |
| Basic EPS Annual | 0.58 | -14.29 | -15.28 | -2.35 | -24.99 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 329.15 | 308.98 | 397.58 | 489.96 | 873.84 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 175.51 | 140.32 | 95.84 | 79.15 | 72.24 | |
| Total Current Liabilities Annual Cr | 248.98 | 252.95 | 246.75 | 200.80 | 170.62 | |
| Total Capital Plus Liabilities Annual Cr | 753.64 | 723.90 | 761.83 | 791.57 | 1138.49 | |
| Fixed Assets Annual | 519.57 | 463.20 | 454.91 | 477.22 | 503.02 | |
| Total Non Current Assets Annual | 570.44 | 518.77 | 473.01 | 499.02 | 524.17 | |
| Total Current Assets Annual | 183.20 | 205.13 | 288.82 | 292.55 | 614.32 | |
| Total Assets Annual | 753.64 | 723.90 | 761.83 | 791.57 | 1138.49 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 643.18 | 372.80 | 411.92 | 368.16 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 37.27 | -10.74 | -52.69 | 38.27 | -82.86 | |
| Cash from Investing Activity Annual | -51.01 | 2.41 | 39.54 | -37.32 | -18.52 | |
| Cash from Financing Annual Activity | 12.82 | 9.01 | 9.83 | -7.20 | 109.39 | |
| Net Cash Flow Annual | -0.92 | 0.67 | -3.32 | -6.26 | 8.02 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 53.69 | 49.63 | 64.24 | 79.43 | 142.19 | |
| ROE Annual % | 1.07 | -28.79 | -23.78 | -2.96 | -17.57 | |
| ROCE Annual % | 3.56 | -11.18 | -16.79 | -0.90 | -6.01 | |
| Total Debt to Total Equity Annual | 0.38 | 0.32 | 0.20 | 0.12 | 0.07 | |
| EBDIT Annual Margin % | 10.86 | -10.96 | -25.52 | 6.18 | -19.83 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 147.27 | 156.18 | 146.25 | 135.27 | 143.99 | 129.14 | 115.57 | 122.91 | 144.78 | 157.54 | 234.20 | 135.68 | 173.17 | |
| Operating Expenses Qtr | 142.50 | 150.65 | 146.58 | 139.50 | 134.60 | 123.84 | 108.96 | 190.51 | 170.92 | 144.02 | 226.15 | 134.00 | 167.33 | |
| Operating Profit Qtr | -6.04 | -0.15 | -3.56 | -10.31 | -5.67 | -8.64 | -3.84 | -79.81 | -30.19 | 11.86 | 6.02 | -1.55 | 0.94 | |
| EBIDT Qtr Cr | 7.51 | 8.31 | 2.44 | 23.51 | 28.77 | 33.07 | 34.38 | -39.86 | 1650.07 | 13.52 | 8.05 | 1.68 | 5.84 | |
| Depreciation Qtr | 8.81 | 9.11 | 9.31 | 9.48 | 9.51 | -16.55 | 9.89 | 10.05 | 11.15 | 10.55 | 10.90 | 11.06 | 11.58 | |
| Net Profit Qtr | -1.43 | -2.20 | -8.29 | 10.98 | -12.68 | 19.37 | 15.70 | -56.14 | 1237.47 | -49.20 | -53.01 | -57.35 | -54.14 | |
| Basic EPS Qtr | -0.23 | -0.37 | -1.35 | 1.79 | -2.07 | 3.16 | 2.56 | -9.17 | 202.03 | -8.03 | -8.65 | -9.36 | -8.84 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 584.97 | 511.61 | 672.20 | 634.78 | 573.75 | |
| Operating Expenses Annual Cr | 579.23 | 557.90 | 675.10 | 548.18 | 512.70 | |
| Operating Profit Annual | -20.06 | -97.96 | -13.87 | 76.63 | 31.36 | |
| Operating Profit Margin Annual % | -3.43 | -19.15 | -2.06 | 12.07 | 5.47 | |
| Total Expenses Annual Cr | 619.52 | 601.47 | 899.60 | 779.11 | 729.90 | |
| EBIDT Annual Cr | 5.74 | -46.30 | -2.90 | 86.61 | 61.05 | |
| EBIDT Annual margin % | 0.98 | -9.05 | -0.43 | 13.64 | 10.64 | |
| Depreciation | 36.71 | 39.12 | 43.66 | 45.59 | 43.22 | |
| PAT Before ExtraOrdinary Items Annual Cr | -1.50 | -33.74 | 1077.90 | -146.28 | -188.19 | |
| Net Profit Annual | -1.17 | -33.24 | 1077.88 | -147.70 | -194.27 | |
| Basic EPS Annual | -0.19 | -5.43 | 175.98 | -24.11 | -31.72 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 842.05 | 826.93 | 852.94 | -246.90 | 179.89 | |
| Minority Interest Liability Annual Cr | -3.82 | -3.49 | -2.98 | -3.00 | -3.04 | |
| Total Non Current Liabilities Annual Cr | 93.62 | 94.24 | 129.78 | 981.40 | 736.45 | |
| Total Current Liabilities Annual Cr | 308.83 | 331.83 | 802.77 | 425.66 | 455.21 | |
| Total Capital Plus Liabilities Annual Cr | 1240.68 | 1271.17 | 1782.51 | 1178.82 | 1390.30 | |
| Fixed Assets Annual | 683.35 | 642.28 | 606.54 | 643.12 | 681.39 | |
| Total Non Current Assets Annual | 755.51 | 702.85 | 741.96 | 667.84 | 707.03 | |
| Total Current Assets Annual | 485.17 | 568.32 | 1040.55 | 510.97 | 683.27 | |
| Total Assets Annual | 1240.68 | 1271.17 | 1782.51 | 1178.82 | 1390.30 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 644.43 | 373.48 | 413.45 | 368.66 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -0.10 | -422.45 | -108.44 | 106.76 | -30.47 | |
| Cash from Investing Activity Annual | 10.23 | 430.33 | 1282.57 | -47.68 | -34.76 | |
| Cash from Financing Annual Activity | -2.81 | -18.37 | -1175.85 | -47.11 | 90.74 | |
| Net Cash Flow Annual | 7.32 | -10.49 | -1.72 | 11.97 | 25.51 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 136.74 | 133.63 | 138.09 | -41.36 | 28.40 | |
| ROE Annual % | -0.13 | -4.04 | 126.99 | 0.00 | -109.75 | |
| ROCE Annual % | -3.32 | -9.09 | -4.75 | 5.44 | 1.90 | |
| Total Debt to Total Equity Annual | 0.02 | 0.02 | 0.04 | -2.92 | 3.47 | |
| EBDIT Annual Margin % | 1.02 | -10.06 | -0.43 | 13.86 | 11.22 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Dr. Rajesh Jain | 49.33 | 89016498 | 0 | 0 |
| Mr. Sandeep Jain | 16.25 | 89016499 | 0 | 0 |
| Mrs. Nirmala Jain | 4.1 | 89016500 | 0 | 0 |
| First Lucre Partnership Co. | 3.68 | 89016514 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|
| Name | Holding Percent | Holding Id |
|---|---|---|
| HUF | 1.9 | 89016522 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Sep 19, 2011 | 0.75 | FINAL | - | Equity Share |
| Sep 16, 2010 | 0.25 | FINAL | - | Equity Share |
| Sep 19, 2008 | 1 | FINAL | - | Equity Share |
| Sep 21, 2007 | 1 | FINAL | - | Equity Share |
| Sep 22, 2006 | 1 | FINAL | - | Equity Share |
| Aug 12, 2005 | 1.5 | FINAL | - | Equity Share |
| Sep 13, 2004 | 1 | FINAL | - | Equity Share |
| Sep 12, 2003 | 1 | FINAL | - | Equity Share |
| Aug 13, 2002 | - | FINAL | - | Equity Share |
| Aug 07, 2001 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Feb 03, 2003 | 10:1 | 2003-02-11 |
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 30, 2024 | Audited Results | - |
| Feb 13, 2024 | Quarterly Results | - |
| Nov 10, 2023 | Quarterly Results | - |
| Aug 12, 2023 | Quarterly Results | - |
| May 30, 2023 | Audited Results | - |
| Feb 14, 2023 | Quarterly Results | - |
| Nov 14, 2022 | Quarterly Results | - |
| Aug 09, 2022 | Quarterly Results | - |
| May 18, 2022 | Audited Results | - |
| Feb 14, 2022 | Quarterly Results | - |
| Feb 01, 2022 | Others | To consider Fund Raising |
| Nov 12, 2021 | Quarterly Results | - |
| Jul 23, 2021 | Quarterly Results | - |
| Jun 02, 2021 | Audited Results | - |
| Feb 12, 2021 | Quarterly Results | - |
| Nov 11, 2020 | Quarterly Results | - |
| Sep 03, 2020 | Quarterly Results | - |
| Jun 29, 2020 | Audited Results | - |
| Feb 14, 2020 | Quarterly Results | - |
| Nov 14, 2019 | Quarterly Results | - |
| Aug 12, 2019 | Quarterly Results | - |
| May 30, 2019 | Audited Results & Dividend | - |
| Feb 26, 2019 | Others | Inter alia, consider and approve raising of funds by the Company through one or more permissible mechanisms as may be deemed appropriate by the Board. |
| Feb 14, 2019 | Quarterly Results | - |
| Nov 14, 2018 | Quarterly Results | - |
| Aug 14, 2018 | Quarterly Results | - |
| May 30, 2018 | Audited Results | - |
| Mar 12, 2018 | Others | Elevation of Dr. Rajesh Jain, Joint Managing Director to the position of Managing Director of the Company. |
| Feb 13, 2018 | Quarterly Results | - |
| Nov 14, 2017 | Quarterly Results | - |
| Sep 13, 2017 | Quarterly Results | - |
| May 26, 2017 | Audited Results | - |
| Feb 14, 2017 | Quarterly Results | - |
| Nov 11, 2016 | Quarterly Results | - |
| Aug 12, 2016 | Quarterly Results | - |
| May 27, 2016 | Audited Results | - |
| Feb 12, 2016 | Quarterly Results | 1. Mr. Mukul Gupta, as a non-executive independent director of the Company, and 2. Mr. Ankesh Jain, as a Whole-time Director and Key Managerial Personnel of the Company. |
| Nov 06, 2015 | Quarterly Results | - |
| Aug 13, 2015 | Quarterly Results | - |
| May 30, 2015 | Audited Results | Revised from 28/05/2015 |
| Feb 13, 2015 | Quarterly Results | - |
| Oct 31, 2014 | Quarterly Results | - |
| Aug 01, 2014 | To consider raising of funds | Raising of funds by way of issue of securities aggregating upto Rs. 250 Crore or equivalent thereof in any currency. |
| May 30, 2014 | Audited Results | - |
| Feb 13, 2014 | Quarterly Results | - |
| Nov 14, 2013 | Quarterly Results | - |
| Aug 08, 2013 | Quarterly Results | - |
| May 30, 2013 | Audited Results & Dividend | - |
| Feb 08, 2013 | Quarterly Results | - |
| Nov 09, 2012 | Quarterly Results | - |
| Aug 07, 2012 | Quarterly Results | - |
| May 18, 2012 | Audited Results & Dividend | To consider the matter pertaining to recommendation / passing over of dividend. |
| Feb 10, 2012 | Quarterly Results | - |
| Oct 21, 2011 | Quarterly Results | - |
| Jul 27, 2011 | Quarterly Results | - |
| May 13, 2011 | Audited Results & Dividend | - |
| Jan 28, 2011 | Redemption of outstanding ZCCBs | To consider the redemption of outstanding Zero Coupon Convertible Bonds aggregating USD 36.8 million, due for redemption on February 14, 2011. |
| Nov 09, 2010 | Quarterly Results | - |
| Jul 20, 2010 | Quarterly Results | - |
| May 07, 2010 | Audited Results & Dividend | - |
| Jan 29, 2010 | Quarterly Results | - |
| Jan 21, 2010 | Others | The Company will now purchase its own fully paid-up 55,92,000 Equity Shares of Re. 1 each at a price not exceeding Rs.229 per Share for an aggregate amount not exceeding Rs. 1,280,568,000. |
| Dec 30, 2009 | Buy Back of Shares | The Board has approved the buy-back of 55,92,000 Equity Shares for an aggregate amount not exceeding Rs. 105.69 Crs & Approved maximum buy-back price as Rs. 189/- per Share through Postal Ballot. |
| Oct 29, 2009 | Quarterly Results | - |
| Jul 30, 2009 | Quarterly Results | - |
| May 27, 2009 | Audited Results & Dividend | To decide not to recommend any dividend on the Equity Shares of the Company for the financial year ended 31st March, 2009. |
| Jan 29, 2009 | Quarterly Results | - |
| Oct 31, 2008 | Quarterly Results | - |
| Jul 28, 2008 | Quarterly Results | - |
| Jun 26, 2008 | Audited Results & Dividend | - |
| Jan 24, 2008 | Quarterly Results | (Revised) |
| Oct 23, 2007 | Quarterly Results | - |
| Jul 24, 2007 | Quarterly Results | - |
| Jan 18, 2007 | Quarterly Results | - |
| Oct 19, 2006 | Quarterly Results | - |
| Jul 20, 2006 | Quarterly Results | - |
| May 22, 2006 | Accounts & Dividend | - |
| Jan 17, 2006 | Quarterly Results | - |
| Oct 25, 2005 | Quarterly Results | - |
| Sep 09, 2005 | Raising of funds | To consider inter-alia, to raise funds from domestic/international markets through issue of Equity Shares/FCDs/PCDs/CDs/FCCBs/Euro Issue and/or other securities aggregating upto Rs.500 Crores. |
| Jul 28, 2005 | Quarterly Results | - |
| May 31, 2005 | Dividend & Accounts | - |
| Jan 29, 2005 | Quarterly Results | - |
| Oct 30, 2004 | Quarterly Results | - |
| Jul 31, 2004 | Quarterly Results | - |
| Jun 30, 2004 | Dividend & Accounts | - |
| Jan 30, 2004 | Quarterly Results | - |
| Oct 29, 2003 | Quarterly Results | - |
| Jul 31, 2003 | Quarterly Results | - |
| May 28, 2003 | Accounts | - |
| Oct 26, 2002 | Quarterly Results | - |
| Jul 31, 2002 | Quarterly Results | - |
| Jun 27, 2002 | Accounts & Final Dividend | - |
| Mar 08, 2002 | Interim Dividend | - |
| Jan 31, 2002 | Quarterly Results | - |
| Oct 31, 2001 | Quarterly Results | - |
| Jul 14, 2001 | Accounts, Dividend, Qtr.Resuls & Others | Declaration of interim dividend on Preference shares on private placement basis. |
| Jan 31, 2001 | Quarterly Results | - |
| Oct 30, 2000 | Quarterly Results | - |
| Jul 25, 2000 | Quarterly Results | - |
| Apr 15, 2000 | Accounts and Dividend | - |
| Mar 31, 2000 | Interim Dividend | - |
| Jan 31, 2000 | Accounts | - |
| Sep 13, 1999 | Dividend-Interim | Int.Dividend on Preference shares issued on pri.placement basis to IDBI etc |
| Jul 30, 1999 | Quarterly Results | - |
| May 15, 1999 | Accounts & Dividend | - |
| Aug 18, 1998 | Final Dividend | - |
| Jul 29, 1998 | Quaterly Results | - |
| May 06, 1998 | Interim Dividend | - |
| Apr 07, 1998 | Increase in Authorised Share Capital | - |
| Nov 29, 1997 | Half Yearly Results | - |
| Jun 25, 1997 | Accounts and dividend | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
05 Jul 2024
PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find attached certificate dated July 02, 2024 issued by Skyline Financial Services Pvt. Ltd., Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for quarter ended June, 2024.
05 Jul 2024
PANACEA BIOTEC LTD. - 531349 - Demat Status Report For The Month Of June, 2024
Please find attached details of shares dematerialized during June, 2024 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
02 Jul 2024
PANACEA BIOTEC LTD. - 531349 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to inform you that NSE and BSE Ltd. have, vide their notice / email dated July 01, 2024, imposed a fine of Rs.11,800 each (inclusive of GST) for non-compliance with the provisions of Regulation 29(2)/29(3) of SEBI LODR Regulations. The detailed disclosure pursuant to SEBI Circular dated July 13, 2023 is attached herewith.
01 Jul 2024
PANACEA BIOTEC LTD. - 531349 - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
We would like to inform you that the Company has received today, a copy of Request for Arbitration filed by Human Vaccine Limited Liability Company, Russia with London court of International Arbitration of dispute between the parties. The details of the said arbitration in the specified format as per the said SEBI Circular is annexed herewith.
27 Jun 2024
PANACEA BIOTEC LTD. - 531349 - Closure of Trading Window
We would like to inform you that the trading window of the Company shall remain closed for all Designated Persons of the Company from July 01, 2024 till completion of 48 hours from the announcement of the unaudited financial results of the Company for quarter ending June 30, 2024 to the Stock Exchanges.
26 Jun 2024
PANACEA BIOTEC LTD. - 531349 - Intimation Regarding Change In Senior Management Personnel Of The Company'S Material Subsidiary Viz. Panacea Biotec Pharma Limited
We would like to inform you that Dr. Shekhar Patel who was working as Chief Executive Officer - US Business of the Company''s material subsidiary, Panacea Biotec Pharma Ltd., has been appointed as Chief Executive Officer of Panacea Biotec Inc. w.e.f. June 26, 2024 and has ceased to be Senior Management Personnel of PBPL at the end of the day on June 25, 2024.
22 Jun 2024
PANACEA BIOTEC LTD. - 531349 - Intimation Of Incorporation Of Step-Down Subsidiary Company
We would like to inform you that the Company''s material subsidiary, Panacea Biotec Pharma Ltd. has incorporated its wholly owned subsidiary company namely, Panacea Biotec Inc. in the state of Delaware, USA and has made an initial investment of US$75,000 (~Rs.6.23 million) in the shares of common stock of Panacea Biotec Inc.
07 Jun 2024
PANACEA BIOTEC LTD. - 531349 - Demat Status Report For The Month Of May, 2024
We would like to inform you that no share has been dematerialised during the month of May, 2024. A copy of the certificate obtained from the Company''s RTA regarding shares dematerialised as on May 31, 2024 is enclosed herewith.
31 May 2024
PANACEA BIOTEC LTD. - 531349 - Re-Designation Of Mr. Ankesh Jain As Whole-Time Director In The Company And Its Wholly Owned Subsidiary, Panacea Biotec Pharma Limited
The Board in its meeting held on 30.05.2024 approved the re-designation of Mr. Ankesh Jain from Whole-time director designated as Director Sales & Marketing to Whole-time Director of the Company for the remaining tenure of his Term i.e. from 01.06.2024 to 31.03.2025. The Board of Directors of the Company''s wholly owned subsidiary company, Panacea Biotec Pharma Ltd. has also re-designated Mr. Ankesh Jain who is currently acting as its non-executive Director, to the position of Whole-time Director w.e.f. 01.06.2024. Mr. Ankesh Jain is not debarred from holding the office of Whole-time director in the Company as well as Panacea Biotec Pharma Ltd, by virtue of SEBI order or any other such authority
31 May 2024
PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith newspaper copies of the Extract of Statement of the Audited Financial Results for the quarter and financial year ended March 31, 2024, published in the newspapers on May 31, 2024.
